Search

Juli S Degraw

from San Diego, CA
Age ~63
Get Report
Also known as:
Juli S Mcgee, Juli S Graw, Juli S Degran, Juli S Degra, Juli S De, Jull Degraw, Jul Degraw, Juli Degrae, Juli Mc Gee, Juli Gee
Phone and address:
3515 Baker St, San Diego, CA 92117
(858) 274-3418
Related to:
Kimberly Gay Hoffman, 65Raymond K Gee, 57Anita Gee, 58John DemontDina Eizerik
Connected to:
Anne M Degraw, 37Carly Degraw, 29Carol P Degraw, 72Carolena A Degraw, 51Donna L Degraw, 60Erin M Degraw, 31George A Degraw, 70Hillary Degraw, 34Kemberli Degraw, 48Kristopher D Degraw, 33

Juli Degraw Phones & Addresses

  • 3515 Baker St, San Diego, CA 92117 (858) 274-3418
  • Laguna Niguel, CA
  • Solana Beach, CA

Work

Position: Medical Professional

Education

Degree: Graduate or professional degree

Resumes

Resumes

Juli Degraw Photo 1

Principal And Managing Director

View page
Location:
San Diego, CA
Industry:
Biotechnology
Work:
Life Science Consulting Group
Principal and Managing Director
Chuv |Lausanne University Hospital Jul 2012 - Mar 2015
Director and Qualified Person, Chuv Oncology Gmp Facility
The Janssen Pharmaceutical Companies of Johnson & Johnson Oct 1986 - Jul 2012
Associate Scientific Director
Education:
Uc San Diego 1978 - 1983
Bachelors, Bachelor of Arts, Biochemistry, Biology
Skills:
Clinical Research
Cell
Regulatory Affairs
Pharmaceutical Industry
Oncology
Clinical Development
Validation
Biomarkers
Quality Assurance
Fda
Sop
Cancer
Gmp
Drug Discovery
Juli Degraw Photo 2

Director At Centre Hospitalier Universitaire Vaudois

View page
Location:
San Diego, California
Industry:
Research
Education:
University of California, San Diego 1978 - 1983
Bachelor of Arts (B.A.), Biochemistry and Cell Biology

Publications

Us Patents

Isolated Cd8 T Lymphocytes Specifically Cytotoxic For A Disease Causing Target Cell

View page
US Patent:
7811816, Oct 12, 2010
Filed:
May 13, 2002
Appl. No.:
10/144188
Inventors:
Zeling Cai - San Diego CA, US
Michael R. Jackson - Del Mar CA, US
Per A. Peterson - Basking Ridge NJ, US
Wei-Xing Shi - San Diego CA, US
Yan Kong - Belle Mead NJ, US
Juli DeGraw - San Diego CA, US
Assignee:
Ortho-McNeil Pharmaeutical, Inc. - Raritan NJ
International Classification:
C12N 5/08
US Classification:
435326
Abstract:
Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.

Ex-Vivo Priming For Generating Cytotoxic T Lymphocytes Specific For Non-Tumor Antigens To Treat Autoimmune And Allergic Disease

View page
US Patent:
7842501, Nov 30, 2010
Filed:
Nov 6, 2007
Appl. No.:
11/935486
Inventors:
Zeling Cai - San Diego CA, US
Michael R. Jackson - Del Mar CA, US
Per A. Peterson - Basking Ridge NJ, US
Wei-Xing Shi - San Diego CA, US
Yan Kong - Belle Mead NJ, US
Juli DeGraw - San Diego CA, US
Assignee:
Ortho-McNeil Pharmaceutical, Inc. - Raritan NJ
International Classification:
C12N 5/08
US Classification:
435372
Abstract:
Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.

Ex-Vivo Priming For Generating Cytotoxic T Lymphocytes Specific For Non-Tumor Antigens To Treat Autoimmune And Allergic Disease

View page
US Patent:
8084253, Dec 27, 2011
Filed:
Oct 6, 2010
Appl. No.:
12/899052
Inventors:
Zeling Cai - San Diego CA, US
Michael R. Jackson - Del Mar CA, US
Per A. Peterson - Basking Ridge NJ, US
Wei-Xing Shi - San Diego CA, US
Yan Kong - Belle Mead NJ, US
Juli DeGraw - San Diego CA, US
Assignee:
Ortho-McNeil Pharmaceutical Corp. - Raritan NJ
International Classification:
C12N 5/02
C12N 5/06
US Classification:
435325, 4353431
Abstract:
Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.

Ex-Vivo Priming For Generating Cytotoxic T Lymphocytes Specific For Non-Tumor Antigens To Treat Autoimmune And Allergic Disease

View page
US Patent:
8084256, Dec 27, 2011
Filed:
Sep 21, 2010
Appl. No.:
12/887032
Inventors:
Zeling Cai - San Diego CA, US
Michael R. Jackson - Del Mar CA, US
Per A. Peterson - Basking Ridge NJ, US
Wei-Xing Shi - San Diego CA, US
Yan Kong - Belle Mead NJ, US
Juli DeGraw - San Diego CA, US
Assignee:
Ortho-McNeil Pharmaceutical Corp. - Raritan NJ
International Classification:
C12N 5/00
C12N 5/02
US Classification:
435372, 435377
Abstract:
Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.

Ex-Vivo Priming For Generating Cytotoxic T Lymphocytes Specific For Non-Tumor Antigens To Treat Autoimmune And Allergic Disease

View page
US Patent:
8106153, Jan 31, 2012
Filed:
Sep 28, 2010
Appl. No.:
12/892068
Inventors:
Zeling Cai - San Diego CA, US
Michael R. Jackson - Del Mar CA, US
Per A. Peterson - Basking Ridge NJ, US
Wei-Xing Shi - San Diego CA, US
Yan Kong - Belle Mead NJ, US
Juli DeGraw - San Diego CA, US
Assignee:
Ortho-McNeil Pharmaceutical Corp. - Raritan NJ
International Classification:
A61K 38/00
US Classification:
530300
Abstract:
Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.

Preparation Of Inactivated Artificial Antigen Presenting Cells And Their Use In Cell Therapies

View page
US Patent:
8124408, Feb 28, 2012
Filed:
Oct 4, 2007
Appl. No.:
11/906807
Inventors:
Zeling Cai - San Diego CA, US
Ann Moriarty - Poway CA, US
Juli Degraw - San Diego CA, US
Didier Leturcq - San Diego CA, US
Wei-Xing Shi - San Diego CA, US
Karen Kabat Stegman - Encinitas CA, US
Xilian Yue - San Diego CA, US
Assignee:
Janssen Pharmaceutica N.V. - Beerse
International Classification:
C12N 5/07
C12N 5/10
US Classification:
435325, 435348, 4353723, 435374, 435375
Abstract:
Methods of processing inactivated artificial antigen presenting cells (aAPCs) and artificial antigen presenting cells with specificity for selected antigenic peptides are described, including their generation and use in cell therapy compositions comprising activated cytotoxic T lymphocytes. Inactivated aAPCs are advantageously generated through crosslinking, such as via a photoreaction involving a psoralen derivative and UVA irradiation.

Ex-Vivo Priming For Generating Cytotoxic T Lymphocytes Specific For Non-Tumor Antigens To Treat Autoimmune And Allergic Disease

View page
US Patent:
8133726, Mar 13, 2012
Filed:
Oct 6, 2010
Appl. No.:
12/899069
Inventors:
Zeling Cai - San Diego CA, US
Michael R. Jackson - Del Mar CA, US
Per A. Peterson - Basking Ridge NJ, US
Wei-Xing Shi - San Diego CA, US
Yan Kong - Belle Mead NJ, US
Juli DeGraw - San Diego CA, US
Assignee:
Ortho-McNeil Pharmaceutical Corp. - Raritan NJ
International Classification:
C12N 5/08
US Classification:
435372
Abstract:
Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.

Ex-Vivo Priming For Generating Cytotoxic T Lymphocytes Specific For Non-Tumor Antigens To Treat Autoimmune And Allergic Disease

View page
US Patent:
8133728, Mar 13, 2012
Filed:
Sep 21, 2010
Appl. No.:
12/887052
Inventors:
Zeling Cai - San Diego CA, US
Michael R. Jackson - Del Mar CA, US
Per A. Peterson - Basking Ridge NJ, US
Wei-Xing Shi - San Diego CA, US
Yan Kong - Belle Mead NJ, US
Juli DeGraw - San Diego CA, US
Assignee:
Ortho-McNeil Pharmaceutical Corp. - Raritan NJ
International Classification:
C12N 5/08
US Classification:
4353723
Abstract:
Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.
Control profile
Juli S Degraw from San Diego, CA, age ~63 Get Report